Banque Transatlantique SA Purchases 1,867,525 Shares of Pfizer Inc. $PFE

Key Points

• Banque Transatlantique SA significantly increased its stake in Pfizer Inc. by 2,787.1%, acquiring a total of 1,934,531 shares, making Pfizer the firm's 23rd largest holding.
• Pfizer recently reported $14.65 billion in revenue for the last quarter, exceeding analyst estimates and showing a 10.3% year-over-year growth.
• The company announced a quarterly dividend of $0.43 per share, which results in an annualized yield of 6.9% for investors.

Banque Transatlantique SA raised its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 2,787.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,934,531 shares of the biopharmaceutical company's stock after purchasing an additional 1,867,525 shares during the period. Pfizer accounts for approximately 0.8% of Banque Transatlantique SA's portfolio, making the stock its 23rd largest holding. Banque Transatlantique SA's holdings in Pfizer were worth $45,302,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Clarity Asset Management Inc. bought a new position in Pfizer during the fourth quarter valued at $27,000. Gould Capital LLC grew its holdings in Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 493 shares during the period. GKV Capital Management Co. Inc. bought a new position in Pfizer during the first quarter valued at $27,000. Bayforest Capital Ltd bought a new position in Pfizer during the first quarter valued at $28,000. Finally, North Capital Inc. bought a new position in Pfizer during the first quarter valued at $28,000. 68.36% of the stock is owned by institutional investors.

Pfizer Trading Up 0.7%

Shares of PFE stock opened at $24.94 on Wednesday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43. The company has a market capitalization of $141.77 billion, a PE ratio of 13.26, a price-to-earnings-growth ratio of 0.88 and a beta of 0.55. The business's fifty day moving average is $24.82 and its 200 day moving average is $24.37.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter last year, the business posted $0.60 earnings per share. The firm's revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, July 25th were given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. The ex-dividend date was Friday, July 25th. Pfizer's dividend payout ratio (DPR) is 91.49%.

Analysts Set New Price Targets

Several equities research analysts have issued reports on PFE shares. Berenberg Bank dropped their target price on Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research report on Thursday, May 29th. Jefferies Financial Group increased their target price on Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research report on Wednesday, May 21st. Bank of America increased their target price on Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Morgan Stanley increased their target price on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 6th. Finally, Citigroup increased their target price on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.